Mona Sarfaty1, Shibao Feng. 1. Department of Prevention and Community Health, George Washington University School of Public Health and Health Services, Washington, DC, USA. mona.sarfaty@jefferson.edu
Abstract
BACKGROUND: Starting in 2001, the state of Maryland established a carefully planned and executed multicomponent intervention to reduce mortality and disparities in colorectal cancer. METHODS: In the most populous county, uninsured participants received education and a choice of free screening by fecal occult blood testing (FOBT) or colonoscopy or both. RESULTS: Over 2 years, a group of 1,672 uninsured individuals, of whom 90% were minorities, registered with the program. Overall, screening uptake was 41% with colonoscopy, 10% with FOBT, and 10% with both FOBT and colonoscopy. CONCLUSION: The choices of colorectal cancer screening modalities by a diverse uninsured population demonstrates the importance of maintaining screening options.
BACKGROUND: Starting in 2001, the state of Maryland established a carefully planned and executed multicomponent intervention to reduce mortality and disparities in colorectal cancer. METHODS: In the most populous county, uninsured participants received education and a choice of free screening by fecal occult blood testing (FOBT) or colonoscopy or both. RESULTS: Over 2 years, a group of 1,672 uninsured individuals, of whom 90% were minorities, registered with the program. Overall, screening uptake was 41% with colonoscopy, 10% with FOBT, and 10% with both FOBT and colonoscopy. CONCLUSION: The choices of colorectal cancer screening modalities by a diverse uninsured population demonstrates the importance of maintaining screening options.
Authors: Annette E Maxwell; Leda L Danao; Catherine M Crespi; Cynthia Antonio; Gabriel M Garcia; Roshan Bastani Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-08 Impact factor: 4.254
Authors: Melinda M Davis; Michele Freeman; Jackilen Shannon; Gloria D Coronado; Kurt C Stange; Jeanne-Marie Guise; Stephanie B Wheeler; David I Buckley Journal: BMC Cancer Date: 2018-01-06 Impact factor: 4.430